ContextVision, a specialist in medical imaging software, has entered a new research collaboration with AMRA Medical to develop advanced diagnostic tools for fatty liver disease (MASLD), a condition affecting up to a quarter of the global population.
The partnership combines ContextVision’s expertise in AI-powered ultrasound imaging with AMRA’s MRI-based body composition technology. Together, the companies aim to create a new, non-invasive method to detect and monitor the progression of liver disease at an early stage.
AMRA Medical now joins this effort by adding their MRI-based analysis for measuring liver fat (PDFF), abdominal fat volumes, and detailed muscle assessment. Their contribution will further enrich the dataset by enabling correlations between MRI and ultrasound imaging biomarkers – strengthening ContextVision’s development of disease staging solutions.
“As we build out our Data Quality business, partnerships like this are essential,” said Gerald Pötzsch, CEO of ContextVision. “AMRA’s highly detailed MRI measurements, add critical value to our clinical data pipeline. Together, we are moving closer to a new standard in liver disease diagnostics – non-invasive, accurate, and scalable.”
Olof Dahlqvist Leinhard, CEO of AMRA Medical, stated, “We’re excited to join ContextVision’s broader initiative to redefine liver diagnostics. Our combined technologies offer a more complete and individualized picture of patient health.”
This collaboration expands ContextVision’s growing network of strategic research partners, which already includes the University of Washington (USA), University of Waterloo (Canada), and InPhase Solutions (Norway).
ContextVision is a software company specialized in image analysis and artificial intelligence. It partners leading manufacturers of ultrasound, X-ray and MRI equipment around the world. Its expertise is to develop software products, based on proprietary technology and artificial intelligence for image-based applications.
AMRA Medical is a health informatics and precision medicine company pioneering body composition analysis. Its technology provides multiple fat and muscle biomarkers derived from rapid whole-body MRI scans.
